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Abstract
Background: Mutations in the KRAS gene are one of the most frequent genetic abnormalities in
ovarian carcinoma. They are of renewed interest as new epidermal growth factor receptor (EGFR)-
targeted therapies are being investigated for use in ovarian carcinoma. As KRAS mutations are
associated with poor response and resistance to EGFR-targeting drugs, this study was conducted
to obtain more information on the spectrum of KRAS mutations in ovarian carcinoma.
Methods: The presence of KRAS mutations in codon 12 and 13 was analyzed in frozen and
formalin-fixed paraffin-embedded (FFPE) tissue with a low density biochip platform. 381 malignant
(29 borderline malignancy, 270 primary carcinomas, and 82 recurrent carcinomas) and 22 benign
tissue samples from a total of 394 patients were examined. KRAS mutational status of each sample
was correlated with dignity, FIGO stage, grade, histology, and survival.
Results: KRAS mutations were found in 60 (15%) samples with 58 samples deriving from malignant
tissue and 2 samples deriving from benign tissue. In 55 (92%) samples codon 12 was found to be
mutated. Frozen and FFPE samples concurred with respect to KRAS mutation status.
Conclusion: KRAS mutation is a common event in ovarian cancer primarily in carcinomas of lower
grade, lower FIGO stage, and mucinous histotype. The KRAS mutational status is no prognostic
factor for patients treated with standard therapy. However, in line with experience from colorectal
cancer and non-small-cell-lung cancer (NSCLC), it may be important for prediction of response to
EGFR-targeted therapies.
Background
According to WHO statistics reported in 2005, ovarian
cancer was ranked 5th in cancer related death in Europe.
As in other tumors, the triggers of ovarian cancer involve
genetic alterations and mutations. The discovery of under-
lying mechanisms that lead to an adverse patient outcome
is of great importance.
Published: 9 April 2009
BMC Cancer 2009, 9:111 doi:10.1186/1471-2407-9-111
Received: 2 December 2008
Accepted: 9 April 2009
This article is available from: http://www.biomedcentral.com/1471-2407/9/111
© 2009 Auner et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Cancer 2009, 9:111 http://www.biomedcentral.com/1471-2407/9/111
Page 2 of 8
(page number not for citation purposes)
One of the best known DNA alterations in a variety of can-
cers is the mutational activation of ras protein family
members. In fact, 20–30% of all human tumors harbour
a mutation in a member of the ras family [1]. In ovarian
cancer, KRAS mutations belong to the most frequently
observed abnormalities [2].
The ras proteins are small GTPases, downstream of EGFR,
which normally cycle between their active and inactive
state. In health, ras proteins are key components in many
pathways that couple growth factor receptors to down-
stream mitogenic effectors involved in cell proliferation
and differentiation.
The most common mutations of these genes are found in
codons 12, 13 and 61, which lead to a constitutively active
ras protein, and subsequently to an inappropriate increase in
proliferation and malignant transformation [1]. In ovarian
cancer, mutations most often affect codons 12 and 13 of the
KRAS gene, with mutation rates reported to be as high as 3–
11% [3,4]. Mutations in codon 61 are rare in ovarian cancer
[5,6], and therefore will not be considered in this study.
It is known that non-small-cell-lung cancer (NSCLC) and
colorectal cancer (CRC) patients with mutant KRAS show
poor response to anti-EGFR therapy [7-10]. Because ovar-
ian cancer patients are also being considered for treatment
with EGFR-targeting substances, and as clinical trials are
already conducted, it is crucial to know whether patients
harbouring a ras mutation may benefit from such therapy.
In this study, 403 malignant and benign samples from 394
patients were analyzed for the presence of mutations in the
KRAS  gene at codons 12 and 13 using a biochip array
hybridization method called GeneStix [11]. To our knowl-
edge, this is the largest number of ovarian cancer samples
analyzed in this manner with the sample size being twice as
large as in the studies of Sieben [12] and Gemignani [13].
Methods
Patients
403 samples from 394 patients were examined. 381
malignant tissue samples (borderline malignancies, pri-
mary and recurrent ovarian carcinomas) from 377
patients and 22 samples from benign tissue (6 ovarian tis-
sues and 16 ovarian cystadenomas) derived from 21
patients were analyzed. More than one sample was avail-
able for a total of 9 patients; including primary and recur-
rent lesions for 3 patients, 2 distinct recurrent lesions for
1 patient, healthy tissue and primary lesions for 2
patients, healthy and borderline tissue for 1 patient, and
cystadenoma and healthy tissue for 2 patients.
170 samples were obtained from patients treated at the
Department of Obstetrics and Gynaecology, Charité Uni-
versity Hospital, Campus Virchow, Berlin. 233 samples
were collected at the Department of Obstetrics and Gynae-
cology, Medical University Vienna, Vienna. Samples were
collected between 1989 and 2006.
Tissue attained in Berlin was fresh frozen to -80°C, and
samples from Vienna were either formalin-fixed paraffin-
embedded (FFPE) (n = 110) or fresh frozen to -80°C (n =
123). Patients gave their written informed consent and the
study was approved by the local institutional review
boards.
Preparation of Samples
FFPE samples were punched out of tissue blocks (Tissue
Microarrayer I; Beecher Instruments, Sun Prairie, USA)
and the DNA was extracted according to Fabjani et al.
[14].
Briefly, the samples were washed repeatedly with xylene
and ethanol and thereafter dried. Each dried pellet was
resuspended in 250 μL of a solution containing 12.5 mg
glass beads (Glass Controlled Pore, 120–200 μm mesh;
Sigma), PCR amplification-buffer, and Proteinase K (0.6
mg/mL). The samples were incubated in an ultrasonic
water bath at 56°C for 30 min followed by incubation at
95°C 10 min in a conventional thermoblock (Eppendorf
AG, Hamburg, Germany) to inactivate proteinase K. Sub-
sequently, the samples were centrifuged and the DNA
containing supernatant was used for further analysis.
DNA from frozen samples obtained in Vienna was isolated
using a salt elution method. Briefly, up to 1 g tissue was pul-
verized with a microdismembrator. The powdered tissue
was suspended in 3 mL lysis buffer (2.34% NaCl, 10 mM
Tris-HCl and 1 mM EDTA, pH = 8). 100 μL solubilizer
(20% sodium dodecyl sulfate solution) and 100 μL of 2%
proteinase K (Sigma-Aldrich, St. Louis, USA) solution were
added. Lysis was performed by overnight incubation at
37°C with gentle agitation. After cooling the sample to
room temperature (RT), 1.4 mL saturated salt solution was
added. The mixture was centrifuged at 10000 × g for 15 min
at RT and DNA was precipitated by adding 2 volumes of
100% ethanol and the supernatant removed. After air-dry-
ing for 5 minutes, DNA was dissolved in 200 μL Tris-EDTA
buffer (10 mM Tris-HCl, 1 mM EDTA, pH = 8).
The DNeasy Blood & Tissue Kit (Qiagen, Hilden, Ger-
many) was used to isolate DNA from samples collected in
Berlin.
Mutation Analysis
The GeneStix biochip platform has been optimized for the
simultaneous detection of 10 frequent mutations found
in codons 12 and 13 of the KRAS gene [11].
The biochip consists of a plastic stick with DNA capture
oligonucleotides immobilized at the tip, and the entirelyBMC Cancer 2009, 9:111 http://www.biomedcentral.com/1471-2407/9/111
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contained in a cylindrical tube. Samples were analyzed by
hybridization to the biochip array after mutant-enriched
PCR as described by Fabjani et al. [15].
In summary, downstream primers were biotin-labeled,
upstream primers were phosphorylated at the 5' position.
20 μL of the PCR products were digested with 1 μL λ-Exo-
nuclease (New England BioLabs, Ipswich, USA) for 30
minutes at RT. In a GeneStix tube, 10 μL of the digested
PCR products were diluted in 200 μL hybridization buffer
including a hybridization control target. Stick hybridiza-
tion was performed at 37°C for 1 h in a conventional ther-
moshaker (Eppendorf AG, Hamburg, Germany).
Without additional washing steps, the biochip was
stained for 15 min with the provided streptavidin-horse-
radish peroxidase conjugate, and thereafter rinsed with 1
mL of assay buffer. The stick was then analyzed with the
GeneStix-Imager, a chemiluminescence detector devel-
oped for use with the GeneStix system. Images were auto-
matically processed with the test-specific analysis software
provided with the imager.
Previously, the assay's limit for detecting KRAS mutations
was determined using 0.1 ng of tumor cell line DNA
mixed with 100 ng of wild-type DNA [11]. Even in this
1000-fold excess of wild-type DNA, GeneStix hybridiza-
tion unambiguously identified all KRAS mutations cov-
ered by the assay. In the same study, 26 stool samples
were analyzed in parallel by biochip hybridization and
sequencing. Biochip-based hybridization detected KRAS
mutations in 9/26 (35%) samples, all of which were con-
firmed by sequencing.
Statistics
To test for differences between groups, in regard to muta-
tion rate, the Pearson's chi-square test was used. Tests
included mutational rates of borderline lesions versus car-
cinoma, primary versus recurrent carcinoma, grade 1
mucinous tumors versus higher grade mucinous tumors,
and the incidence of recurrence in primary carcinoma.
For deeper insight into factors consisting of more than
two groups, such as overall and mucinous histotype grad-
ing (1–3), FIGO stage (I–III), and nodal status in carci-
noma, and for histology (serous, mucinous,
endometrioid, others/unknown) in all malignant sam-
ples, a residual analysis with adjusted standardized resid-
uals was done.
To test for relation between patient age and the muta-
tional rate, a Mann-Whitney-U test was performed.
For patients with primary ovarian cancer overall and
recurrence free survival was calculated with univariate Log
rank and Cox regression adjusted for FIGO. All statistical
calculations were conducted with SPSS 15.0 (SPSS Inc;
Chicago, IL, USA).
Results
Basic results
Of the 403 samples examined, 60 (15%) contained muta-
tions at codon 12 or 13. The most frequent mutation was
asp12 (40%) followed by val12 (23%) and cys12 (13%).
Overall, 92% of the mutations were located in codon 12.
Two patients carried double mutations (Table 1).
Overall, mutations were more common in borderline
lesions (35%) than in primary carcinoma (16%) and
recurrent ovarian carcinoma (6%). Two of the 16 ovarian
cystadenoma samples contained mutations, no mutation
was found in healthy ovarian tissue.
Multiple samples were analyzed from 9 patients. A KRAS
mutation was detected in only one of these. Of this
patient, the primary and recurrent lesion could be ana-
lyzed and identical mutations were found in both lesions.
Mucinous lesions displayed mutations most frequently.
The mutational rate increased from 50% in mucinous
borderline lesions to 60% in primary tumors of the same
histotype (Tables 2 and 3). In serous lesions KRAS muta-
tions occurred less frequently. Compared to mucinous
lesions, serous malignancies exhibited a relatively high
mutational frequency in borderline tumors (35%) and
fewer mutations in carcinoma (9%) (Tables 2 and 3).
Table 1: KRAS mutations examined samples
mutation amino acid n %
GGT → GAT gly12 → asp12 24 40
GGT → TGT gly12 → cys12 8 13
GGT → GTT gly12 → val12 14 23
GGT → GCT gly12 → ala12 4 7
GGT → CGT gly12 → arg12 2 3
GGC → GAC gly13 → asp13 4 7
GGC → TGC gly13 → cys13 1 2
GGT → GCT/GAT gly12 → ala12/asp12 2 3
GGT → GTT/GAT gly12 → val12/asp12 1 2
total 60 100BMC Cancer 2009, 9:111 http://www.biomedcentral.com/1471-2407/9/111
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Data from primary carcinoma was split up into FFPE and
fresh frozen samples. Overall the percentage of mutation
was very similar (14% in FFPE tissue vs. 16% in fresh fro-
zen tissue). Divided according to histotype the results
were comparable. The only exception was seen in the
mutational rate of mucinous tumors. This rate was much
higher in FFPE samples. This is probably an artefact
caused by the small sample size for this particular histo-
type (Table 4).
Statistical results
Pearson's chi-square test was used to compare mutation
rates of borderline to cancerous lesions and primary to
recurrent disease.
Borderline lesions more frequently contained mutations
than tumors (p = 0.003), and the rate of mutation was sig-
nificantly higher in primary tumors than recurrent tumors
(p = 0.023).
To get more insight into the relation between the muta-
tion rate of carcinoma, nodal status, tumor grade (1–3),
and FIGO classification (I–III) residual analysis was used.
Tumors with different grading showed a significant differ-
ence in mutation frequency.
Grade 1 tumors exhibited a significantly higher muta-
tional rate than grade 3 tumors (p < 0.0001). We found no
significant difference in mutational rates in patients with
different FIGO stages, but a trend towards a higher muta-
tional rate could be seen in FIGO stage I tumors (p =
0,081). No differences were found in rates of mutation
related to nodal status.
When malignant samples were compared with respect to
histology, the mutational rate in mucinous lesions was
significantly higher than in lesions of other histotypes,
whereas serous malignancies harboured significantly less
KRAS mutations (p < 0.0001).
Because KRAS mutations are a typical feature of mucinous
lesions, we studied the results of this subtype more
closely. Similar to the statistical results independent of
histotype, the mutation rates are significant higher in
grade 1 carcinoma compared to higher grade mucinous
tumors (p = 0,007).
We also found, that tumors originating from younger
patients more frequently contained a KRAS  mutation
(Mann-Whitney-U, p = 0.063). No statistical difference
was found between the groups of patients with and with-
out recurrence.
Furthermore, no significant difference could be found in
recurrence free and overall survival, between patients with
mutated and wildtype KRAS  tumors. The log-rank test
resulted in p-values of 0.258 for recurrence free, and 0.567
for overall survival respectively. FIGO corrected Cox
regression showed p-values of 0.865 and 0.656 for recur-
rence free and overall survival.
Discussion
As of late KRAS mutations in ovarian cancer should stand
in the center of attention again due to the availability of
EGFR-targeted therapies (e.g. Gefitinib, Erlotinib, and
Cetuximab), that are already in use to treat patients with
NSCLC and metastatic CRC. These therapies are under
discussion for treatment of ovarian cancer and numerous
clinical trials are already in progress [16], however, not all
patients respond equally to this treatment. In patients
with NSCLC and CRC mutations in EGFR lead to a better
prognosis under this medication [17-19], others show
marginal if any response. Recently, KRAS  activational
mutations have been associated with a lack of sensitivity
to anti-EGFR substances by maintaining the ability to con-
tinue aberrant signalling through the EGFR pathway, cir-
cumventing the blocked EGFR [7-10].
It has been shown that EGFR mutations do not play a role
in ovarian cancer [20], while KRAS mutations are very
well documented [3,4,6,21].
The frequency of KRAS mutations was similar in frozen
and FFPE tissue, indicating that our method is suitable for
KRAS analysis in both types of tissue.
The mutation frequency found in borderline malignan-
cies (34%) and carcinomas (13%), is well in line with pre-
vious reports [3-5,22]. Not surprisingly, benign ovarian
tissue contained a minimal number of mutations.
Overall, the mutation rate in mucinous malignancies is
much higher than in lesions of any other histological sub-
type. It is likely that KRAS mutation is associated with
mucinous differentiation [23] as these mutations also
accumulate in mucinous carcinomas obtained from other
Table 2: KRAS mutation frequencies observed in borderline 
malignancies
borderline
histotype n mutated % mutated
serous 20 7 35.00
endometroid 1 0 0.00
mucinous 6 3 50.00
unknown 2 0 0.00
total 29 10 34.48BMC Cancer 2009, 9:111 http://www.biomedcentral.com/1471-2407/9/111
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Table 3: KRAS mutation frequencies observed in carcinoma
primary carcinoma recurrent carcinoma carcinoma total
n mutated % mutated n mutated % mutated n mutated % mutated
270 43 15.93 82 5 6.10 352 48 13.64
histotype
serous 177 17 9.60 69 4 5.80 246 21 8.54
endometroid 34 4 11.76 5 0 0.00 39 4 10.26
mucinous 25 15 60.00 5 1 20.00 30 16 53.33
clear cell 19 5 26.32 2 0 0.00 21 5 23.81
undifferent. 10 0 0.00 1 0 0.00 11 0 0.00
unknown 5 2 40.00 5 2 40.00
age
≤ 50 72 16 22.22 31 4 12.90 103 20 19.42
> 50 198 27 13.64 51 1 1.96 249 28 11.24
grading
1 33 17 51.52 7 0 0.00 40 17 42.50
2 90 14 15.56 27 4 14.81 117 18 15.38
3 141 12 8.51 46 1 2.17 187 13 6.95
4 1 0 0.00 0 0 0.00 1 0 0.00
unknown 5 0 0.00 2 0 0.00 7 0 0.00
FIGO stage
1 65 17 26.15 9 0 0.00 74 17 22.97
2 31 5 16.13 8 0 0.00 39 5 12.82
3 145 17 11.72 48 4 8.33 193 21 10.88
4 28 4 14.29 13 1 7.69 41 5 12.20
unknown 1 0 0.00 4 0 0.00 5 0 0.00BMC Cancer 2009, 9:111 http://www.biomedcentral.com/1471-2407/9/111
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organs [24]. In agreement with other studies, a lower
mutation rate was found in mucinous borderline malig-
nancies compared to carcinoma [4,24].
In line with other studies, we also find a smaller percent-
age of samples harbouring a mutation in serous border-
line tumors than in serous carcinoma. In serous lesions
KRAS mutation seems to be a typical feature of borderline
tumors and low grade carcinoma. On the other hand,
KRAS mutation does not seem to play a major role in high
grade serous carcinoma. Russel and McCluggage [25] and
also Kurman and Shih [21] proposed a new theory that
distinguishes between high grade and low grade serous
carcinoma and tries to reconstruct the different steps of
development in those entities. KRAS,  BRAF  and  PTEN
mutations seem to be a feature of tumors with low malig-
nant potential, whereas high grade carcinoma, which
account for 90% of all serous carcinoma, harbour TP53
mutations and genetic instability [21]. The results of our
study may not supply a new foundation for this theory;
however, it stands well in line with the established notion
of two separate pathways for the development of high and
low grade serous ovarian carcinoma.
When KRAS mutational status was analyzed irrespective
of histotype, grade 1 tumors showed a significantly higher
mutational rate than grade 3 tumors. This is probably due
to the predominance of serous samples in the group of
high grade tumors. An almost equal number of serous and
mucinous lesions are present in the group of grade 1
tumors. The group of grade 2 tumors contain 5 times
more, and the group of grade 3 tumors over 50 times more
serous than mucinous lesions. As stated above, serous
tumors seldom harbour a KRAS mutation. Even if a muta-
tion occurs, it will appear more probable in serous lesions
with low malignant potential which would even amplify
the described effect.
The higher number of KRAS mutations in lower grade
samples could also be an explanation for the higher muta-
tional rate in younger patients. Various studies have
shown that patients with lower grading seem to be of
younger age than patients with high grading [21].
Mutant and wildtype primary carcinoma showed no sig-
nificant difference regarding the incidence of recurrent
disease (p = 0.114). There is also no difference in recur-
rence free survival or overall survival. Therefore, KRAS
mutation cannot be considered a prognostic factor for
standard chemotherapy.
The percentage of analyzed recurrent tumors bearing a
mutation was therefore surprisingly low. The imbalance
may be explained by the relatively small sample size of
recurrent carcinomas and may be lost in the large sample
variation.
One of the patients for whom multiple samples were ana-
lyzed, showed a mutation in the KRAS gene. As this muta-
tion was found in both the primary carcinoma and the
recurrent lesion, the mutational event must have taken
pN
0 104 17 16.35 19 0 0.00 123 17 13.82
1 67 7 10.45 28 4 14.29 95 11 11.58
x 99 19 19.19 35 1 2.86 134 20 14.93
Table 3: KRAS mutation frequencies observed in carcinoma (Continued)
Table 4: KRAS mutations in FFPE tissue and frozen tissue
FFPE tissue frozen tissue
histotype n mutated % mutated n mutated % mutated
serous 50 2 4,00 127 15 11,81
mucinous 9 8 88,89 16 7 43,75
others 29 3 10,34 39 8 20,51
total 88 13 14,77 182 30 16,48BMC Cancer 2009, 9:111 http://www.biomedcentral.com/1471-2407/9/111
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place in the primary lesion previous to the processes that
led to recurrent disease.
Diebold et al. report six cases where tissue was taken from
two contralateral borderline tumor masses harbouring a
KRAS mutation. In all cases the mutations were present in
each of the paired tumors examined [26]. Ho et al.
detected corresponding mutations in borderline malig-
nancies and the adjacent cystadenoma epithelium [27].
Therefore it could be concluded that mutations of KRAS
are an early event in development of low grade tumors.
Our finding of one paired mutated primary and recurrent
tumor is hardly enough evidence, but supports earlier
findings from other groups and further supports the
notion that such mutations are an early event in the
malignant process.
Conclusion
In summary, KRAS mutation is a common event in ovar-
ian cancer and is more frequently present in carcinoma of
lower grade, lower FIGO stage, and in lesions of mucinous
histotype. Our results support earlier findings from other
groups in a very large number of samples. KRAS mutation
was not found to be of prognostic value for patients under
standard therapy, but these mutations could emerge as an
important factor for individually tailored anti-EGFR ther-
apies.
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